Scinopharm Taiwan (TPE:1789) Total Stockholders Equity: NT$10,461 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
69 GF Score
Price NT$18.30
GF Value NT$20.04
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Total Stockholders Equity?

Scinopharm Taiwan TPE:1789 -1.61% 69 Total Stockholders Equity is NT$10,461 Mil as of Jun. 2026. GuruFocus rates TPE:1789 with a GF Score™ of 69/100 and a GF Value™ of NT$20.04 (Fairly Valued). The stock has 8 warning signs investors should review.

Scinopharm Taiwan's Total Stockholders Equity for the quarter that ended in Jun. 2026 was NT$10,461 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Scinopharm Taiwan's Book Value per Share for the quarter that ended in Jun. 2026 was NT$13.23. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Scinopharm Taiwan's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.08.

Scinopharm Taiwan  (TPE:1789) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Scinopharm Taiwan's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(10461.414-0)/790.739
=13.23

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Scinopharm Taiwan's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(208.726 + 664.364) / 10461.414
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Total Stockholders Equity Related Terms

Scinopharm Taiwan Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Total Stockholders Equity Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10,511.05 10,450.05 10,364.43 10,525.80 10,524.74

Scinopharm Taiwan Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10,268.46 10,992.95 10,524.74 10,312.84 10,461.41
TPE:1789
69GF Score
Scinopharm Taiwan Ltd TPE:1789
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of NT$10,461 Mil mean?
Scinopharm Taiwan (TPE:1789) has a Total Stockholders Equity of NT$10,461 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Total Stockholders Equity too high?
Scinopharm Taiwan's current Total Stockholders Equity is NT$10,461 Mil. Overall, Scinopharm Taiwan has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Total Stockholders Equity compare to ZTS?
Scinopharm Taiwan's Total Stockholders Equity of NT$10,461 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Total Stockholders Equity is NT$10,461 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Fairly Valued. The stock's GF Value™ is NT$20.04, compared to a current price of NT$18.30 — trading 8.7% below its estimated fair value. The current Total Stockholders Equity is NT$10,461 Mil. Scinopharm Taiwan's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Total Stockholders Equity is NT$10,461 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$18.30 is trading 8.7% below its estimated GF Value™ of NT$20.04. GuruFocus considers Scinopharm Taiwan to be Fairly Valued.

Key valuation signals for TPE:1789:

  • Total Stockholders Equity: NT$10,461 Mil
  • GF Value™: NT$20.04 vs. price of NT$18.30 (8.7% below fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
69GF Score

Get the complete analysis for TPE:1789

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.30
Price
NT$20.04
GF Value